Bayer stock holds steady as intraday Xetra trading stays near EUR 48.82

Published on 09/07/2026 at 15:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bayer stock traded almost unchanged around EUR 48.82 on Xetra on September 7, 2026, following a prior-session close of EUR 48.84 and modest moves within a tight intraday range, while investors continue to weigh recent analyst views and earlier deal news.

Forscherin im weißen Kittel pipettiert an einem beleuchteten Laborarbeitsplatz vor einem Bildschirm mit 3D-Molekülstruktur — Pharmazeutisches Forschungslabor – Wissenschaftlerin mit Pipette, Molekülstruktur-Monitor, blaue LED-Beleuchtung, Illustration mit AI erstellt.

Bayer AG (ISIN DE000BAY0017) stock traded largely unchanged around EUR 48.82 in Xetra trading on September 7, 2026, keeping close to the prior closing level of EUR 48.84 from September 4, 2026 and reflecting only a small intraday move within a tight range according to market data.finanzen.ch

Intraday trading around prior close

As of 12:28 on September 7, 2026, Bayer stock was quoted at EUR 48.82 on Xetra, effectively defending the previous session’s level and placing the shares among the neutral movers in the DAX 40 index.finanzen.ch Earlier in the same September 7, 2026 session the stock had opened at EUR 48.59 and briefly traded down to an intraday low of EUR 48.30 before recovering toward EUR 48.82.finanzen.ch

The latest intraday pattern builds on the last completed Xetra session on September 4, 2026, when Bayer closed at EUR 48.84, down about 1.5 percent from the prior day, after moving between a low of EUR 48.42 and a high of EUR 49.73.ms-aktuell.de That earlier closing level remained slightly below a recent peak near EUR 50 recorded in early September 2026, underlining that the stock is trading just under a short-term high but without a pronounced breakout move.ms-aktuell.de

Analyst views and recent rating actions

Recent analyst coverage shows differing degrees of optimism on Bayer stock, offering investors additional context for the current sideways trading pattern.finanzen.ch According to a ratings overview dated September 7, 2026, JPMorgan Chase & Co. carries an Overweight stance on Bayer as of September 3, 2026, while UBS AG reiterated a Buy rating on September 1, 2026 and Jefferies & Company Inc. maintained a Hold recommendation on August 10, 2026.finanzen.ch The spread between Buy, Overweight and Hold ratings illustrates that, even with supportive views from some houses, the market remains divided on the medium-term upside for the stock.

For investors, this mixed analyst picture means that individual expectations about earnings recovery, litigation risks and the impact of past portfolio moves still play a decisive role in positioning. The fact that Bayer stock on September 4, 2026 traded noticeably below a recent intraday high of around EUR 50 suggests that positive factors such as the company’s multibillion-euro agreement with Apollo, mentioned in market commentary earlier in September 2026, have not yet translated into a sustained rally and may be counterbalanced by ongoing risk considerations.ms-aktuell.de

Recent performance and risk context

Market data for September 4, 2026 show that Bayer stock underperformed the DAX index, which managed a modest percent gain while Bayer slipped about 1.5 percent from its prior close to EUR 48.84.ms-aktuell.de The underperformance highlights how company-specific issues can overshadow a generally supportive index environment, particularly when investors remain cautious about legacy litigation exposures and the pace of operational improvement.

Trading volume on Xetra on September 4, 2026 was reported at several million shares, with liquidity concentrated around the EUR 49 mark, indicating active but balanced participation between buyers and sellers as the shares moved within a narrow intraday corridor from EUR 48.42 to EUR 49.73.ms-aktuell.de Against that backdrop, the nearly unchanged intraday quote of EUR 48.82 around midday on September 7, 2026 suggests that the stock is consolidating just below the short-term high near EUR 50 rather than extending the prior decline or embarking on a new upward leg.finanzen.ch

Pharmaceuticals and crop science as core businesses

Bayer’s business model centers on pharmaceuticals, consumer health and crop science, providing a diversified earnings base across prescription medicines, over-the-counter brands and agricultural solutions. For shareholders, developments in high-margin drug franchises and in crop protection demand are crucial, because they shape the company’s ability to grow revenue and improve profitability over time. Even when no fresh quarterly figures are released within the last few days, expectations for these segments influence how investors interpret every small move in the stock price around levels such as EUR 48.82 and EUR 48.84 as observed on September 7 and September 4, 2026.

Stock level and investor takeaway

With Bayer stock quoted at EUR 48.82 on Xetra as of 12:28 on September 7, 2026, the shares are trading just below the earlier September 2026 intraday high near EUR 50 and only marginally under the last completed close of EUR 48.84 from September 4, 2026, signaling a consolidation phase rather than a decisive trend move.finanzen.ch The modest 1.5 percent decline in the prior session and the subsequent stabilization around the same price area show that the market is waiting for the next fundamental catalyst, while recent analyst ratings ranging from Buy and Overweight to Hold underline the balanced risk-reward perception among professional observers.finanzen.ch